Brought to you by 
Series D round brings €65mm to Ganymed
19 Nov 2013
Executive Summary
Cancer-focused Ganymed Pharmaceuticals raised €65mm ($82mm) in its Series D venture round. ATS Beteiligungsverwaltung GMBH led and was joined by Future Capital, MIG Verwaltungs AG, and private investors. Funds will be used to continue developing various preclinical solid tumor drug candidates.
Deal Industry
- Pharmaceuticals
- Research, Analytical Equipment & Supplies
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series D round brings €65mm to Ganymed
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice